Amyris and ImmunityBio JV for next gen Covid-19 RNA vaccine
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
The drug will be marketed under the brand name Molnaflu
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Subscribe To Our Newsletter & Stay Updated